The efficacy of adalimumab in the treatment of hidradenitis suppurativa

Year 2018, , 19 - 27, 17.03.2018

Ali Balevi Pelin Ustuner , Mustafa Özdemir

https://doi.org/10.5798/dicletip.407240

Abstract

Objectives:  Hidradenitis  suppurativa  is  seen  as  a  result  of  the  occlusion,  constriction  and  bacterial  infection  of  the apocrine  glands  in  bilateral  axillas,  submammarian  areas,  neck,  inguinal  regions,  flexural  surfaces  of  the  thighs  and anogenital areas. Among the biological agents adalimumab is a recombinant human IgG1 monoclonal antibody; TNF-α antagonist approved to be used in the treatment of hidradenitissuppurativa. 

Methods: In this study, 12 patients resistant to conventional treatments with moderate severity, Hurley stage 2 or 3 were started subcutaneous adalimumab treatment. The disease activities upon the hidradenitis suppurativa, clinical severity index and life quality index of the patients were examined both before and 1 year after the treatment. 

Results: Twelve  patients were recruited. In the examination of  the  hidradenitis  suppurativa  clinical  severity  scores, significant  clinical  responses  were  noted  in  9  (75%)  patients.  While  the  mean  value  of  the  life  quality  index  was 14.4±6.9 before the treatment, it was determined to be significantly decreased to 4.3±3.8 after the treatment.

Conclusion:  We  concluded  that  adalimumab;  the  unique  biological  agent  approved  to  be  used  in  the  treatment  of treatment-resistant, moderate-severe hidradenitis suppurativa is efficient and safe in similar ratios with the previous clinical studies in the literature.

Keywords

Adalimumab, eccrine glands

References

• 1. Gönül M, Gül Ü.Hidradenitis Süpürativa. Türk Dermatoloji Dergisi. 2009;3:9-12.
• 2. Ingram JR, Woo PN, Chua SL, Ormerod AD, Desai N, Kai AC, et al. Interventions for hidradenitissuppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality. British Journal of Dermatology. 2016;174:970-8.
• 3. Dominique C, Mekkes JR, Tzellos T. Randomized Controlled Trials for the Treatment of Hidradenitis Suppurativa. Dermatol Clin. 2016;34:69-80.
• 4. Zhang J, Reeder VJ, Hamzavi IH. Use of biologics in the treatment of hidradenitis suppurativa: a review of the Henry Ford Hospital experience. Br J Dermatol. 2014;171:1600-2.
• 5. Kimball AB, Jemec GB, Yang M,Kageleiry A,Signorovitch JE, Okun MM, et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for Hidradenitis suppurativa treatment. British Journal of Dermatology. 2014;171:1434-42.
• 6. Napolitano M, Megna M, Timoshchuk EA, Patruno C, Balato N, Fabbrocini G, et al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clin Cosmet Investig Dermatol. 2017;10:105-15.
• 7. Balık E, Eren T, Yamaner S, Bulut T, Buğra D, Büyükuncu Y,ve ark. Gluteal Yerleşimli Yaygın Hidradenitis Supurativa ile İlgili Cerrahi Deneyimlerimiz.Kolon Rektum Hast Derg. 2007;17:27-32.
• 8. Mehdizadeh A, Hazen PG, Bechara FG, Zwingerman N, Moazenzadeh M, Bashash M, et al. Recurrence of hidradenitis suppurativa after surgical management: A systematic review and meta-analysis. J Am Acad Dermatol. 2015;73:70-7.
• 9. Makris GM, Poulakaki N, Papanota AM, Kotsifa E, Sergentanis TN, Psaltopoulou T. Vulvar, Perianal and Perineal Cancer After Hidradenitis Suppurativa: A Systematic Review and Pooled Analysis. Dermatol Surg. 2017;43:107-15.
• 10. Blok JL, Hattem S, Jonkman M.F, Horváth B et al. Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review. Br J Dermatol. 2013;168:243-52.
• 11. Chinniah N, Cains GD. Moderate to severe hidradenitis suppurativa treated with biological therapies. Australasian Journal of Dermatology. 2014;55:128-31.
• 12. Deckers IE, Prens EP. An Update on Medical Treatment Options for Hidradenitis Suppurativa. Drugs. 2016;76:215-29.
• 13. van Rappard DC, Limpens J, Mekkes JR. The off-label treatment of severe hidradenitis suppurativa with TNF-αinhibitors: a systematic review. Journal of Dermatological Treatment. 2013;24:392-404.
• 14. Fotiadou C, Vakirlis E, Ioannides D. Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa. Clinical, Cosmetic and Investigational Dermatology. 2016;9:367-72.
• 15. Alhusayen R, Shear NH. Scientific evidence for the use of current traditional systemic the rapies in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2015;73:42-6.
• 16. Kim ES, Garnock KP, Keam SJ. Adalimumab: A Review in Hidradenitis Suppurativa. Am J Clin Dermatol. 2016;17:545-52.
• 17. Fimmel S, Zoubouli CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermato endocrinol. 2010;2:9-16.
• 18. Chinniah N, Cains GD. Moderate to severe hidradenitis suppurativa treated with biological therapies. Australasian Journal of Dermatology. 2014;55:128-31.
• 19. Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhász I, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J EurAcad Dermatol Venereol. 2015;29:619-44.
• 20. Martin-Ezquerra G, Masferrer E, Pujol RM. Use of biological treatments in patients with hidradenitis suppurativa. G Ital Dermatol Venereol. 2017;152:373-78.
• 21. Weber P, SeyedJafari SM, Yawalkar N, et al Hunger RE. Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients. J Am Acad Dermatol. 2017;76:1189-91.